Preview Mode Links will not work in preview mode

Aug 20, 2019

Chronic Lymphocytic Leukemia Update, Issue 1, 2019 — Part 1: Our most recent one-on-one interview with Dr Wierda featuring emerging research and cases from his practice:

  • Evolution of the treatment paradigm for patients with chronic lymphocytic leukemia (CLL) (00:00)
  • Biomarker assessment for patients with newly diagnosed CLL (03:27)
  • Therapeutic approach for older patients with CLL; IGHV mutation status in treatment decision-making (06:41)
  • Case: A woman in her early 70s with CLL with deletion 17p, a p53 mutation and no IGHV mutation achieves a complete remission with ibrutinib and venetoclax as first-line therapy on a clinical trial (10:40)
  • Implications of del(17p) and p53 mutations in CLL pathogenesis and for the selection of treatment (12:03)
  • Efficacy of venetoclax alone and in combination with obinutuzumab or rituximab (15:40)
  • Phase II trial of ibrutinib with venetoclax for CLL (20:04)
  • Ongoing Phase II CAPTIVATE trial of ibrutinib with venetoclax as front-line therapy (22:20)
  • Relevance of minimal residual disease (MRD) as a clinical endpoint in CLL (24:54)
  • Effect of MRD status on outcomes in the Phase III MURANO trial evaluating venetoclax with rituximab for relapsed/refractory CLL (28:02)
  • Risk of tumor lysis syndrome (TLS) with venetoclax (32:02)
  • Prophylactic approaches for TLS associated with venetoclax (35:00)
  • Ongoing Phase III trial of ibrutinib and venetoclax; evaluation of ibrutinib/venetoclax in combination with an anti-CD20 antibody (37:02)
  • Potential clinical role of ibrutinib/venetoclax for patients with CLL (41:27)
  • Case: A man in his late 50s with idiopathic thrombocytopenic purpura and del(11q) CLL with no IGHV mutation receives acalabrutinib after multiple lines of therapy, including venetoclax and ibrutinib (43:23)
  • Efficacy and side-effect profile of acalabrutinib versus ibrutinib (48:39)
  • Results of the Phase III ASCEND study of acalabrutinib alone versus investigator’s choice of idelalisib/rituximab or bendamustine/rituximab for relapsed/refractory CLL (54:34)
  • Ongoing Phase III ELEVATE-TN trial of acalabrutinib alone versus acalabrutinib/obinutuzumab versus chlorambucil/obinutuzumab for previously untreated CLL (56:14)
  • Emerging data with next-generation, reversible Bruton tyrosine kinase inhibitors for CLL (1:00:34)
  • Mechanism of action, efficacy and tolerability of the recently FDA-approved antibody-drug conjugate moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia (1:02:24)
  • Case: A woman in her early 60s with del(17p) CLL and no IGHV mutation receives venetoclax and obinutuzumab as first-line therapy (1:05:51)
  • Activity and safety profile of chimeric antigen receptor (CAR) T-cell therapy for CLL (1:08:40)
  • Challenges in the clinical management of CLL (1:13:29)

CME information and select publications